Notice ID: 3e07557a5f5b4067aa2c6e0f10f42da3Special Notice
Evaluating ADME of compounds from dystonia project
Archived on September 1, 2023. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 4:00 PM UTC−04:00
- Posted
- August 10, 2023
- Notice type
- Special Notice
- NAICS
- 541380: Testing Laboratories and Services
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH NIDA
- Place of performance
- Louisville, KY, 40202
- Last updated
- Dec 4, 2025
Identifiers
- Solicitation number
- 75N95023Q00574
- Notice ID
- 3e07557a5f5b4067aa2c6e0f10f42da3
Description
NOTICE OF INTENT to Sole Source SOLICITATION NUMBER: 75N95023Q00574 TITLE: Evaluating ADME of compounds from dystonia project CLASSIFICATION CODE: B504 Special Studies/Analysis-Chemical/Biological NAICS CODE: 541380 Testing Laboratories and Services RESPONSE DATE: August 17, 2023, 4:00 pm EST PRIMARY POINT OF CONTACT: Michele Pastorek michele.pastorek@nih.gov Phone: 301.827.1739 DESCRIPTION: INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). National Center for Advancing Translational Sciences (NCATS) intends to negotiate on a sole source basis with Pharmaron, Inc for evaluating ADME of compounds from dystonia. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE and SET ASIDE STATUS The intended procurement is classified under NAICS code 541380 Testing Laboratories and Services with a Size Standard of $19 Million. REGULATORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 Simplified Acquisition Procedures. Contracts awarded using FAR Part 13 Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6 Competition Requirements. FAR Subpart 13.106-1 (b) Soliciting from a single source provides that: For purchases not exceeding the simplified acquisition threshold, Contracting Officers may solicit from one source IF the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name OR industrial mobilization). The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2023-04 dated June 02, 2023 DESCRIPTION OF REQUIREMENT PURPOSE AND OBJECTIVES: The purpose of this requirement is to evaluate ADME of compounds from dystonia from Pharmaron, Inc. QTY: 1 CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION The essential characteristics of these PK studies that limit the availability to a sole source are the required consistency of the results. Only this suggested source can furnish the requirements, to the exclusion of other sources, because only this suggested source (PHARMARON) is familiar with the class of compounds that are being evaluated. They have formulated and dosed analogs from the same chemical series, and in this contract will evaluate new analogs from the same chemical series. Consistency and reproducibility are essential to draw meaningful conclusions and comparison to previous analogs from the same series. The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, Pharmaron, Inc., is the only vendor in the marketplace that can provide the services required by NCATS . The intended source is: Pharmaron, Inc. 201 E. Jefferson Streeet, Suite 304 Louisville, KY 40202-1249 CLOSING STATEMENT THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responses must be received by the closing date and time of this announcement and must reference the solicitation number 75N95023Q00574. Responses must be submitted electronically to Michele Pastorek, Contract Specialist, at Michele.pastorek@nih.gov and Valerie Whipple, Contracting Officer, at valerie.whipple@nih.gov. U.S. Mail and fax responses will not be accepted.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
75N95023Q00574- Special NoticeCurrentAug 10, 2023
Evaluating ADME of compounds from dystonia project
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Louisville VAMC seeks a contract for laboratory services to run surface sample testing and personnel aseptic technique competency testing results (gloved fingertip and thumb sampling and media fill testing) for the Pharmacy Service s sterile compounding spaces. | - | Pre-Solicitation | 11/02/2026 |
***** This Amendment is to Extend the Due Time to 3:00 PM EST 17 April 2026 *****The work required under this agreement will primarily involve analysis of water, chlorophyll, phytoplankton, and benthic macroinvertebrates samples. All work shall be performed in strict compliance with the attached specifications and all other terms, clauses, and conditions incorporated herein. Quotes are due on 17 April 2026 at 11:00 AM Eastern Time. | - | Solicitation | 04/17/2026 |
Centers for Disease Control (CDC) is issuing this synopsis as a means of conducting market research to identify parties having an interest in and the resources to support this requirement for a California-based integrated health care system to serve as an electronic health record site in CDC’s VISION 2.0 respiratory pathogen surveillance network, providing integrated, longitudinal medical, laboratory, pharmacy, vaccination, claims, and outcomes data to support influenza surveillance, vaccine-effectiveness studies, and related respiratory pathogen research across emergency/urgent care, inpatient, and intensive care unit (ICU) settings. The result of this market research will contribute to determining the method of acquisition. The applicable North American Industry Classification System (NAICS) code assigned to this acquisition is 541380- Testing Laboratories and Services. | - | Market Research | 12/04/2026 |
THIS IS A SOURCES SOUGHT ANNOUNCEMENT ONLY. It is neither a solicitation announcement nor a request for proposals or quotes and does not obligate the Government to award a contract. Requests for a solicitation will not receive a response. Responses to this sources sought must be in writing. The purpose of this sources sought announcement is for market research to make appropriate acquisition decisions and to gain knowledge of potential qualified Small Businesses interested and capable of providing the services described below. NIH-OD-SS-27-000058 The information gained from this market research will help the National Institutes (NIH) Clinical Center (CC) plan for its acquisition strategy. Potential Large and Small Businesses shall include business information outlined in the section below as a part of their response. Complete responses to this notice shall be in the following format: SAM UEI Number and CAGE code Company Name Company Address, City, State and Zip Code Company Point of Contact, Email Address and Telephone Number Current GSA Schedule appropriate to this Sources Sought of other FAR Part 8 considerations Socioeconomic Status: (i.e., HUBZone, 8a, Small Business, Women Owned Small Business, Veteran-Owned Small-Business, etc.) https://www.sam.gov. Provide a capability statement that addresses the organizations qualifications and ability to perform as a contractor for the work described in the Statement of Work. The NIH Clinical Center Office of Research Support and Compliance (ORSC) is seeking a qualified and experienced contractor to provide project management and coordination of routine and emergent qualification, calibration/PM and certification services, including repairs and replacements, for the departments/ICs located at the NIH’s Bethesda, MD campus. Please see attached SOW for more details. Contractors shall not reach out to the customer for any questions or clarifications. All communications must go through contracting. ****************************************************************************** Important information: The Government is not obligated to nor will it pay for or reimburse any costs associated with responding to this source sought synopsis request. This notice shall not be construed as a commitment by the Government to issue a solicitation or ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. The Government will in no way be bound to this information if any solicitation is issued. No sub-contracting opportunity is anticipated. NAICS: The North American Classification System (NAICS) code for this acquisition is 541380. PSC: H966 Notice to potential offerors: All offerors who provide goods or services to the United States Federal Government must be registered and have an active registration in the System for Award Management (SAM) at www.sam.gov and complete Online Representations and Certifications Application (ORCA). All interested Offerors should submit information by e-mail to ryssa.nix@nih.gov. Please use subject line “Response to NIH-OD-SS-27-000058”. All information submissions shall be received no later than noon on November 15, 2026. | - | Pre-Solicitation | 11/15/2026 |
INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to: Alcami Corporation 2320 Scientific Park DR Wilmington, North Carolina 28405-1800 NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 541380 with a Size Standard $16.6M. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01, March 13, 2026. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION Title: Stability Testing for ManNAc Drug Product produced in Campaigns 5 and 6. Stability testing will occur under regulatory compliance Background Information: NHGRI was gifted 48kg of unlabeled drug ManNAc (powder-in-sachet) in September 2025, and agreed to take over the FDA-required, mandatory, stability testing program of this drug that has been ongoing at Alcami Corporation since June 2024. The gifted drug was produced in 2 campaigns, Campaign 5 (C5, June 2024) and Campaign 6 (C6, September 2024). NHGRI plans to use the donated clinical grade drug for upcoming clinical trials. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by November 9, 2026 at 9:00 AM Eastern time and must reference solicitation number 75N98027Q00040. Responses may be submitted electronically to Mr. James Law, Contracting Officer at James.Law@nih.gov. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.” | - | Pre-Solicitation | 11/09/2026 |
Additional Details
Solicitation Number
75N95023Q00574
Archive Date
Sep 1, 2023
Office Address
Bethesda, MD, 20892